Media
Press Release
01
2025.01
Completion Of Enrollment Of Phase III Clinical Trial Of The Company’s Novel Adjuvanted Recombinant Shingles Vaccine REC610
23
2024.10
Initiation Of Phase III Clinical Trial In China Of The Company’s Novel Adjuvanted Recombinant Shingles Vaccine Rec610
20
2024.08
Jiangsu Recbio Technology Co., Ltd. announced 2024 interim results report and latest progress
26
2024.03
Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project
Publications
2023.03.06
Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
Download
2022.05.11
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
2022.02.12
Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
2021.11.09
A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques